数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Bruce D. Broussard Director, Chief Executive Officer 61 1632.74万美元 16.08 2024-03-08
John W. Garratt Independent Director 55 32.60万美元 0.13 2024-03-08
Karen W. Katz Independent Director 67 34.66万美元 0.06 2024-03-08
Wayne A. I. Frederick Independent Director 52 36.49万美元 0.04 2024-03-08
Raquel C. Bono Independent Director 67 34.50万美元 0.04 2024-03-08
Marcy S. Klevorn Independent Director 64 35.19万美元 0.04 2024-03-08
Brad D. Smith Independent Director 60 31.11万美元 0.04 2024-03-08
Frank A. D'Amelio Independent Director 66 36.36万美元 2.06 2024-03-08
Kurt J. Hilzinger Chairman of the Board, Independent Director 63 60.13万美元 1.94 2024-03-08
David T. Feinberg Independent Director 62 32.15万美元 0.04 2024-03-08
Jorge S. Mesquita Independent Director 62 35.16万美元 0.17 2024-03-08

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Bruce D. Broussard Director, Chief Executive Officer 61 1632.74万美元 16.08 2024-03-08
Susan M. Diamond Chief Financial Officer 50 473.07万美元 1.86 2024-03-08
Vishal Agrawal -- Chief Strategy and Corporate Development Officer 49 未披露 未持股 2024-03-08
Sam M. Deshpande Chief Information Officer 59 未披露 未持股 2024-03-08
William K. Fleming Chief Corporate Affairs Officer 56 320.74万美元 未持股 2024-03-08
Joseph C. Ventura Chief Legal Officer 47 359.88万美元 2.08 2024-03-08
George Renaudin II President, Medicare & Medicaid 55 305.25万美元 0.41 2024-03-08
John Paul W. Felter Senior Vice President, Chief Accounting Officer and Controller 40 未披露 未持股 2024-03-08
James A. Rechtin President and Chief Operating Officer 52 未披露 未持股 2024-03-08
Sanjay K. Shetty President, CenterWell 50 458.19万美元 0.02 2024-03-08
Timothy S. Huval Chief Administrative Officer 57 373.46万美元 未持股 2024-03-08

董事简历

中英对照 |  中文 |  英文
Bruce D. Broussard

Bruce D. Broussard被任命为本公司的总裁和首席执行官并被选举进董事会。在每一种情况下,2013年1月1日生效完成了长达一年担任首席执行官角色的过渡计划。2011年12月,Broussard先生加入Humana担任总裁。在加入Humana之前,Broussard先生是McKesson Specialty/US Oncology, Inc的首席执行官。2010年12月,US Oncology被McKesson收购。在US Oncology,他担任了很多高级执行职位,包括首席财务官,总裁,首席执行官和董事会主席。Broussard先生也是商业圆桌会议成员和美国健康保险计划(AHIP)的董事会成员,也任职于AHIP执行委员会。


Bruce D. Broussard,serves as Director and Chief Executive Officer (Principal Executive Officer), having held these positions since January 1, 2013. Mr. Broussard was elected President upon joining the Company in December 2011 and served in that capacity through December 2012. Prior to joining the Company, Mr. Broussard was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Mr. Broussard served in a number of senior executive roles, including Chief Financial Officer, Chief Executive Officer, and Chairman of the Board.
Bruce D. Broussard被任命为本公司的总裁和首席执行官并被选举进董事会。在每一种情况下,2013年1月1日生效完成了长达一年担任首席执行官角色的过渡计划。2011年12月,Broussard先生加入Humana担任总裁。在加入Humana之前,Broussard先生是McKesson Specialty/US Oncology, Inc的首席执行官。2010年12月,US Oncology被McKesson收购。在US Oncology,他担任了很多高级执行职位,包括首席财务官,总裁,首席执行官和董事会主席。Broussard先生也是商业圆桌会议成员和美国健康保险计划(AHIP)的董事会成员,也任职于AHIP执行委员会。
Bruce D. Broussard,serves as Director and Chief Executive Officer (Principal Executive Officer), having held these positions since January 1, 2013. Mr. Broussard was elected President upon joining the Company in December 2011 and served in that capacity through December 2012. Prior to joining the Company, Mr. Broussard was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Mr. Broussard served in a number of senior executive roles, including Chief Financial Officer, Chief Executive Officer, and Chairman of the Board.
John W. Garratt

John W. Garratt自2015年12月2日起担任公司执行副总裁和首席财务官。他于2014年10月加入Dollar General担任金融&战略高级副总裁,后从2015年7月到2015年12月担任代理首席财务官。加入Dollar General之前,Garratt从2004年5月到2014年10月在Yum!Brands, Inc.(世界上最大的酒店公司)担任多个职位,曾担任企业战略和金融规划领导职位。他从2013年10月到2014年10月担任KFC分部以及Pizza Hut分部和Yum Restaurants International金融副总裁和分部总监。他还从2010年3月到2013年10月担任Yum Corporate Strategy高级主管;直接向企业首席财务官报告,领导企业战略和推进重要的跨区域活动。Garratt从2004年5月到2010年3月在Yum担任多个其他金融职位。他从2002年4月到2004年5月担任Alcoa Inc.工厂总监;1999年3月到2002年4月担任General Electric 金融管理职位。他于1990年5月加入Alcoa开始自己的职业生涯,在该公司任职了将近9年。


John W. Garratt,was initially elected to the Board in February 2020. Mr. Garratt was formerly the President and Chief Financial Officer of Dollar General Corporation, having held this position from September 2022 to June 2023. Mr. Garratt joined Dollar General in October 2014 as Senior Vice President, Finance & Strategy and subsequently served as Interim Chief Financial Officer from July 2015 to December 2015 and most recently served as Executive Vice President and Chief Financial Officer from December 2015 to September 1, 2022. Prior to joining Dollar General, Mr. Garratt held various positions of increasing responsibility with Yum! Brands, Inc., one of the world's largest restaurant companies, between May 2004 and October 2014, holding leadership positions in corporate strategy and financial planning. Mr. Garratt served as Vice President, Finance and Division Controller for the KFC division and earlier for the Pizza Hut division and for Yum Restaurants International between October 2013 and October 2014. Mr. Garratt also served as the Senior Director, Yum Corporate Strategy, from March 2010 to October 2013, reporting directly to the corporate Chief Financial Officer and leading corporate strategy as well as driving key cross-divisional initiatives. Mr. Garratt served in various other financial positions at Yum from May 2004 to March 2010. Prior to his career at Yum! Brands, Mr. Garratt served as Plant Controller for Alcoa Inc. between April 2002 and May 2004, and held various financial management positions at General Electric from March 1999 to April 2002. He began his career in May 1990 at Alcoa, where he served for approximately nine years. Mr. Garratt also serves on the Board of Directors of Papa John's International, Inc. and Cracker Barrel Old Country Store, Inc.
John W. Garratt自2015年12月2日起担任公司执行副总裁和首席财务官。他于2014年10月加入Dollar General担任金融&战略高级副总裁,后从2015年7月到2015年12月担任代理首席财务官。加入Dollar General之前,Garratt从2004年5月到2014年10月在Yum!Brands, Inc.(世界上最大的酒店公司)担任多个职位,曾担任企业战略和金融规划领导职位。他从2013年10月到2014年10月担任KFC分部以及Pizza Hut分部和Yum Restaurants International金融副总裁和分部总监。他还从2010年3月到2013年10月担任Yum Corporate Strategy高级主管;直接向企业首席财务官报告,领导企业战略和推进重要的跨区域活动。Garratt从2004年5月到2010年3月在Yum担任多个其他金融职位。他从2002年4月到2004年5月担任Alcoa Inc.工厂总监;1999年3月到2002年4月担任General Electric 金融管理职位。他于1990年5月加入Alcoa开始自己的职业生涯,在该公司任职了将近9年。
John W. Garratt,was initially elected to the Board in February 2020. Mr. Garratt was formerly the President and Chief Financial Officer of Dollar General Corporation, having held this position from September 2022 to June 2023. Mr. Garratt joined Dollar General in October 2014 as Senior Vice President, Finance & Strategy and subsequently served as Interim Chief Financial Officer from July 2015 to December 2015 and most recently served as Executive Vice President and Chief Financial Officer from December 2015 to September 1, 2022. Prior to joining Dollar General, Mr. Garratt held various positions of increasing responsibility with Yum! Brands, Inc., one of the world's largest restaurant companies, between May 2004 and October 2014, holding leadership positions in corporate strategy and financial planning. Mr. Garratt served as Vice President, Finance and Division Controller for the KFC division and earlier for the Pizza Hut division and for Yum Restaurants International between October 2013 and October 2014. Mr. Garratt also served as the Senior Director, Yum Corporate Strategy, from March 2010 to October 2013, reporting directly to the corporate Chief Financial Officer and leading corporate strategy as well as driving key cross-divisional initiatives. Mr. Garratt served in various other financial positions at Yum from May 2004 to March 2010. Prior to his career at Yum! Brands, Mr. Garratt served as Plant Controller for Alcoa Inc. between April 2002 and May 2004, and held various financial management positions at General Electric from March 1999 to April 2002. He began his career in May 1990 at Alcoa, where he served for approximately nine years. Mr. Garratt also serves on the Board of Directors of Papa John's International, Inc. and Cracker Barrel Old Country Store, Inc.
Karen W. Katz

Karen W. Katz,自2020年8月起担任The RealReal, Inc.董事会成员。她曾担任Casper Sleep的董事(从2019年4月到2022年1月)。Melton女士目前是风险投资公司Adeft Capital的首席执行官和创始人,自2018年8月起她在那里工作。从2005年到2018年6月,Melton女士担任时代华纳公司全球公共政策执行副总裁,在那里她管理与世界各国政府的互动,并为公司的各种合并交易获得批准发挥了重要作用。在此之前,她曾担任Viacom全球政府关系执行副总裁8年,在那里她曾帮助领导1999年对哥伦比亚广播公司(CBS Corp)的最初收购,然后管理合并后公司的政策运营。Melton女士是JBG Smith(纽约证券交易所代码:JBGS)和华盛顿特区经济俱乐部(Economic Club of Washington, d.c。)的董事会成员,也是对外关系委员会(Council on Foreign Relations)的成员。她持有维克森林大学(Wake Forest University)的文学学士学位,佛罗里达大学(University of Florida)的新闻与传播硕士学位,以及美国大学华盛顿法学院(the American University Washington College of Law)的法学博士学位。


Karen W. Katz,was initially elected to the Board in September 2019. Ms. Katz was most recently interim CEO of Intermix, LLC from June 2022 to December 2022. Prior to Intermix, Ms. Katz served as the President and CEO of Neiman Marcus Group LTD LLC from 2010 to February 2018. Neiman Marcus Group is an international multibrand omni-channel retailer whose portfolio of brands includes Neiman Marcus, Bergdorf Goodman and MyTheresa. Having joined Neiman Marcus in 1985, Ms. Katz served in key executive and leadership roles in the company's merchant, stores and eCommerce organizations as Executive Vice President—Stores, a member of the Office of the Chairman of Neiman Marcus Group, and President, Neiman Marcus Online, and President and CEO, Neiman Marcus Stores. Ms. Katz currently serves on the Board of Directors of Under Armour, Inc. and The RealReal, Inc.
Karen W. Katz,自2020年8月起担任The RealReal, Inc.董事会成员。她曾担任Casper Sleep的董事(从2019年4月到2022年1月)。Melton女士目前是风险投资公司Adeft Capital的首席执行官和创始人,自2018年8月起她在那里工作。从2005年到2018年6月,Melton女士担任时代华纳公司全球公共政策执行副总裁,在那里她管理与世界各国政府的互动,并为公司的各种合并交易获得批准发挥了重要作用。在此之前,她曾担任Viacom全球政府关系执行副总裁8年,在那里她曾帮助领导1999年对哥伦比亚广播公司(CBS Corp)的最初收购,然后管理合并后公司的政策运营。Melton女士是JBG Smith(纽约证券交易所代码:JBGS)和华盛顿特区经济俱乐部(Economic Club of Washington, d.c。)的董事会成员,也是对外关系委员会(Council on Foreign Relations)的成员。她持有维克森林大学(Wake Forest University)的文学学士学位,佛罗里达大学(University of Florida)的新闻与传播硕士学位,以及美国大学华盛顿法学院(the American University Washington College of Law)的法学博士学位。
Karen W. Katz,was initially elected to the Board in September 2019. Ms. Katz was most recently interim CEO of Intermix, LLC from June 2022 to December 2022. Prior to Intermix, Ms. Katz served as the President and CEO of Neiman Marcus Group LTD LLC from 2010 to February 2018. Neiman Marcus Group is an international multibrand omni-channel retailer whose portfolio of brands includes Neiman Marcus, Bergdorf Goodman and MyTheresa. Having joined Neiman Marcus in 1985, Ms. Katz served in key executive and leadership roles in the company's merchant, stores and eCommerce organizations as Executive Vice President—Stores, a member of the Office of the Chairman of Neiman Marcus Group, and President, Neiman Marcus Online, and President and CEO, Neiman Marcus Stores. Ms. Katz currently serves on the Board of Directors of Under Armour, Inc. and The RealReal, Inc.
Wayne A. I. Frederick

Wayne A. I. Frederick于2020年2月当选为董事会成员。他自2014年7月起担任霍华德大学校长。在此之前,弗雷德里克博士在担任教务长兼首席代表后,于2013年10月当选霍华德大学临时校长。学术干事一年多。在得克萨斯大学医学博士安德森癌症中心从事博士后研究和外科肿瘤学研究金后,弗雷德里克博士开始了他在康涅狄格大学癌症中心副主任的学术生涯。回到霍华德大学后,他的学术职位包括医学院副院长,外科系主任,癌症中心主任和卫生科学副教务长。他还于2011年获得了霍华德大学商学院的工商管理硕士学位。Frederick博士继续为霍华德大学医学院的医学生和住院医师开展讲座。弗雷德里克(Frederick)博士是美国外科医生学院(American College of Surgeons)的会员,隶属于众多外科组织,包括美国外科协会(American Surgical Association)。除其他一些私人控股公司和慈善组织外,Frederick博士还担任Mutual of America Life Insurance Co.的董事会成员。


Wayne A. I. Frederick,has served on Insulet Corporation Board of Directors since October 2020. He is the President Emeritus of Howard University, having previously served as the President from July 2014 to September 2023. He is also the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine. Prior to being appointed president in 2014, Dr. Frederick served as Howard University's Provost and Chief Academic Officer. Dr. Frederick is a practicing surgeon, distinguished researcher and scholar, and the author of numerous peer-reviewed articles, book chapters, abstracts, and editorials. He has received several awards for his scholarship and public service and lectures to medical students and residents of Howard's College of Medicine. Dr. Frederick belongs to numerous surgical organizations, including the American Surgical Association, and is a member of the American College of Surgeons Academy of Master Surgeon Educators and the National Academy of Medicine. As a widely recognized expert on disparities in healthcare and medical education, his medical research focuses on narrowing racial, ethnic, and gender disparities in cancer care outcomes among African Americans and other underrepresented groups. Dr. Frederick has served as the principal investigator for major collaborations with the National Cancer Institute and Johns Hopkins University, as well as several national minority-serving oncology programs. He received his Bachelor of Science, Doctor of Medicine, and Master of Business Administration from Howard University.
Wayne A. I. Frederick于2020年2月当选为董事会成员。他自2014年7月起担任霍华德大学校长。在此之前,弗雷德里克博士在担任教务长兼首席代表后,于2013年10月当选霍华德大学临时校长。学术干事一年多。在得克萨斯大学医学博士安德森癌症中心从事博士后研究和外科肿瘤学研究金后,弗雷德里克博士开始了他在康涅狄格大学癌症中心副主任的学术生涯。回到霍华德大学后,他的学术职位包括医学院副院长,外科系主任,癌症中心主任和卫生科学副教务长。他还于2011年获得了霍华德大学商学院的工商管理硕士学位。Frederick博士继续为霍华德大学医学院的医学生和住院医师开展讲座。弗雷德里克(Frederick)博士是美国外科医生学院(American College of Surgeons)的会员,隶属于众多外科组织,包括美国外科协会(American Surgical Association)。除其他一些私人控股公司和慈善组织外,Frederick博士还担任Mutual of America Life Insurance Co.的董事会成员。
Wayne A. I. Frederick,has served on Insulet Corporation Board of Directors since October 2020. He is the President Emeritus of Howard University, having previously served as the President from July 2014 to September 2023. He is also the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine. Prior to being appointed president in 2014, Dr. Frederick served as Howard University's Provost and Chief Academic Officer. Dr. Frederick is a practicing surgeon, distinguished researcher and scholar, and the author of numerous peer-reviewed articles, book chapters, abstracts, and editorials. He has received several awards for his scholarship and public service and lectures to medical students and residents of Howard's College of Medicine. Dr. Frederick belongs to numerous surgical organizations, including the American Surgical Association, and is a member of the American College of Surgeons Academy of Master Surgeon Educators and the National Academy of Medicine. As a widely recognized expert on disparities in healthcare and medical education, his medical research focuses on narrowing racial, ethnic, and gender disparities in cancer care outcomes among African Americans and other underrepresented groups. Dr. Frederick has served as the principal investigator for major collaborations with the National Cancer Institute and Johns Hopkins University, as well as several national minority-serving oncology programs. He received his Bachelor of Science, Doctor of Medicine, and Master of Business Administration from Howard University.
Raquel C. Bono

Raquel C. Bono最初于2020年9月当选为董事会成员。她是RCB咨询公司的负责人,自2019年10月起担任负责人。博诺博士是一名获得董事会认证的创伤外科医生,美国海军医疗队退役副上将,此前曾担任国防卫生局(DHA)首席执行官和局长。在首席执行官和局长职位上,博诺博士领导了一个联合、综合作战支援机构,使美军医疗服务的所有分支机构能够在和平时期和战争时期向作战司令部提供医疗保健服务。博诺博士为陆军、海军、空军和海军陆战队整合了一个前所未有的价值500亿美元的全球医疗企业,由50家医院和300家诊所组成,为950万军人提供医疗服务,监督国防部电子医疗记录的部署,并促进了双方的合作最大的联邦卫生系统的国防部和退伍军人事务部(VA)。博诺博士自1991年起担任美国外科学会(ACS)研究员,曾在ACS理事会和州长健康政策和倡导工作组任职。先后荣获国防杰出服役奖章、国防高级服役奖章3枚、功勋军团奖章4枚、功勋服役奖章2枚、海军陆战队表彰奖章2枚。博诺博士也在几家私人控股公司的董事会任职。


Raquel C. Bono,was initially elected to the Board in September 2020. Dr. Bono is a Principal at RCB Consulting having held this position since October 2019. Dr. Bono most recently served as Chief Health Officer at Viking Cruises from November 2020 until her retirement in December 2023. Prior to Viking Cruises, Dr. Bono, a board-certified trauma surgeon and retired Vice Admiral, U.S. Navy Medical Corps, previously served as the Chief Executive Officer and Director for the Defense Health Agency (DHA). In this capacity, Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel, oversaw the Department of Defense deployment of the electronic health record, and facilitated the collaboration between the largest federated health systems of the Department of Defense and Department of Veterans Affairs (VA). An American College of Surgeons (ACS) Fellow since 1991, Dr. Bono served on the ACS Board of Governors and the Governors Health Policy and Advocacy Workgroup. She has been honored with the Defense Distinguished Service Medal, three Defense Superior Service Medals, four Legion of Merit Medals, two Meritorious Service Medals, and two Navy and Marine Corps Commendation medals. Dr. Bono currently serves on the Board of Directors of Alcon, Inc.
Raquel C. Bono最初于2020年9月当选为董事会成员。她是RCB咨询公司的负责人,自2019年10月起担任负责人。博诺博士是一名获得董事会认证的创伤外科医生,美国海军医疗队退役副上将,此前曾担任国防卫生局(DHA)首席执行官和局长。在首席执行官和局长职位上,博诺博士领导了一个联合、综合作战支援机构,使美军医疗服务的所有分支机构能够在和平时期和战争时期向作战司令部提供医疗保健服务。博诺博士为陆军、海军、空军和海军陆战队整合了一个前所未有的价值500亿美元的全球医疗企业,由50家医院和300家诊所组成,为950万军人提供医疗服务,监督国防部电子医疗记录的部署,并促进了双方的合作最大的联邦卫生系统的国防部和退伍军人事务部(VA)。博诺博士自1991年起担任美国外科学会(ACS)研究员,曾在ACS理事会和州长健康政策和倡导工作组任职。先后荣获国防杰出服役奖章、国防高级服役奖章3枚、功勋军团奖章4枚、功勋服役奖章2枚、海军陆战队表彰奖章2枚。博诺博士也在几家私人控股公司的董事会任职。
Raquel C. Bono,was initially elected to the Board in September 2020. Dr. Bono is a Principal at RCB Consulting having held this position since October 2019. Dr. Bono most recently served as Chief Health Officer at Viking Cruises from November 2020 until her retirement in December 2023. Prior to Viking Cruises, Dr. Bono, a board-certified trauma surgeon and retired Vice Admiral, U.S. Navy Medical Corps, previously served as the Chief Executive Officer and Director for the Defense Health Agency (DHA). In this capacity, Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel, oversaw the Department of Defense deployment of the electronic health record, and facilitated the collaboration between the largest federated health systems of the Department of Defense and Department of Veterans Affairs (VA). An American College of Surgeons (ACS) Fellow since 1991, Dr. Bono served on the ACS Board of Governors and the Governors Health Policy and Advocacy Workgroup. She has been honored with the Defense Distinguished Service Medal, three Defense Superior Service Medals, four Legion of Merit Medals, two Meritorious Service Medals, and two Navy and Marine Corps Commendation medals. Dr. Bono currently serves on the Board of Directors of Alcon, Inc.
Marcy S. Klevorn

Marcy S. Klevorn最初于2021年2月当选为董事会成员。Klevorn女士曾于2019年5月担任福特汽车公司的首席转型官,直至2019年10月退休。在首席转型官职位上,她通过帮助完善福特汽车公司治理系统、促进企业更快地采用敏捷团队以及确保整个企业的流程改进,加速了福特汽车公司的转型。她还促进了与关键技术合作伙伴的战略合作,并支持福特汽车公司的多元化努力。Klevorn女士于1983年加入福特汽车公司,担任福特汽车公司信息技术部门的主要执行和领导职务,包括首席信息官办公室主任和集团信息技术副总裁,负责监督福特IT工具和人才的转型。Klevorn女士还曾担任福特汽车公司(Ford Motor Company)旗下的福特智能移动有限责任公司(Ford Smart Mobility LLC)的执行副总裁兼总裁,负责监督某些收购和其他投资,并帮助加快公司在新兴移动服务和全球数据洞察与分析领域的设计、建设、发展和投资计划。Klevorn女士目前在北方信托公司和一些私营公司的董事会任职。


Marcy S. Klevorn,was initially elected to the Board in February 2021. Ms. Klevorn was formerly the Chief Transformation Officer of Ford Motor Company from May 2019 until her retirement in October 2019. In this role, she accelerated the company's transformation by helping to refine its corporate governance systems, facilitate faster adoption of agile teams across the business and ensure process improvements across the enterprise. She also facilitated strategic partnerships with key technology partners and supported the company's diversity efforts. Having joined Ford Motor Company in 1983, Ms. Klevorn served in key executive and leadership roles within the company's information technology organization including Director of the Office of the Chief Information Officer and Group Vice President of Information Technology. Ms. Klevorn also served as Executive Vice President and President of Ford Smart Mobility LLC, a division of Ford Motor Company, where she oversaw certain acquisitions and other investments and helped to accelerate the company's plans to design, build, grow and invest in emerging mobility services and global data insight and analytics. Ms. Klevorn currently serves on the Board of Directors of Northern Trust Corporation and Cerence Inc. in addition to a few privately held companies.
Marcy S. Klevorn最初于2021年2月当选为董事会成员。Klevorn女士曾于2019年5月担任福特汽车公司的首席转型官,直至2019年10月退休。在首席转型官职位上,她通过帮助完善福特汽车公司治理系统、促进企业更快地采用敏捷团队以及确保整个企业的流程改进,加速了福特汽车公司的转型。她还促进了与关键技术合作伙伴的战略合作,并支持福特汽车公司的多元化努力。Klevorn女士于1983年加入福特汽车公司,担任福特汽车公司信息技术部门的主要执行和领导职务,包括首席信息官办公室主任和集团信息技术副总裁,负责监督福特IT工具和人才的转型。Klevorn女士还曾担任福特汽车公司(Ford Motor Company)旗下的福特智能移动有限责任公司(Ford Smart Mobility LLC)的执行副总裁兼总裁,负责监督某些收购和其他投资,并帮助加快公司在新兴移动服务和全球数据洞察与分析领域的设计、建设、发展和投资计划。Klevorn女士目前在北方信托公司和一些私营公司的董事会任职。
Marcy S. Klevorn,was initially elected to the Board in February 2021. Ms. Klevorn was formerly the Chief Transformation Officer of Ford Motor Company from May 2019 until her retirement in October 2019. In this role, she accelerated the company's transformation by helping to refine its corporate governance systems, facilitate faster adoption of agile teams across the business and ensure process improvements across the enterprise. She also facilitated strategic partnerships with key technology partners and supported the company's diversity efforts. Having joined Ford Motor Company in 1983, Ms. Klevorn served in key executive and leadership roles within the company's information technology organization including Director of the Office of the Chief Information Officer and Group Vice President of Information Technology. Ms. Klevorn also served as Executive Vice President and President of Ford Smart Mobility LLC, a division of Ford Motor Company, where she oversaw certain acquisitions and other investments and helped to accelerate the company's plans to design, build, grow and invest in emerging mobility services and global data insight and analytics. Ms. Klevorn currently serves on the Board of Directors of Northern Trust Corporation and Cerence Inc. in addition to a few privately held companies.
Brad D. Smith

Brad D. Smith, Smith 先生自2008年以来一直任Intuit董事,目前Intuit公司的总裁兼首席执行官。 Smith 先生于2003年加入Intuit,曾担任高级副总裁兼总经理,从2006年到2007年任小商业部门高级副总裁兼总经理,从2005年到2006年任QuickBooks高级副总裁兼总经理,从2004年到2005年消费税收集团高级副总裁兼总经理,从2003年到2004年Intuit公司的会计中心和开发网络部门的副总裁和总经理。在加入Intuit之前, Smith 先生担任ADP的营销和业务发展高级副总裁,在这里从1996年到2003年他担任了好几个高管职务。 Smith 先生曾在雅虎的董事会工作。从2010年到2013年。 Smith 先生被任命为Nordstrom公司的董事。2013年6月,他是审计委员会和财务委员会的一个成员。 Smith 先生持有马歇尔大学的工商管理学士学位和阿奎那大学的硕士学位。


Brad D. Smith,was initially elected to the Board in September 2022. Mr. Smith is the President of Marshall University, having held this position since January 2022. Prior to joining Marshall, Mr. Smith was Executive Chairman of the Board of Intuit Inc. from January 2019 until January 2022 and Chairman from January 2016 until January 2019, following 11 years as Intuit's President and CEO from January 2008 until December 2018. Mr. Smith began his career at Intuit in February 2003, and prior to his time as President and CEO, he served in various leadership positions within the company. Prior to joining Intuit, Mr. Smith held several executive positions with ADP, where he served from 1996 to 2003. Mr. Smith holds a Bachelor of Business Administration degree from Marshall University and a Master's degree in Management from Aquinas College. Mr. Smith currently serves on the Board of Directors of Amazon.com, Inc.
Brad D. Smith, Smith 先生自2008年以来一直任Intuit董事,目前Intuit公司的总裁兼首席执行官。 Smith 先生于2003年加入Intuit,曾担任高级副总裁兼总经理,从2006年到2007年任小商业部门高级副总裁兼总经理,从2005年到2006年任QuickBooks高级副总裁兼总经理,从2004年到2005年消费税收集团高级副总裁兼总经理,从2003年到2004年Intuit公司的会计中心和开发网络部门的副总裁和总经理。在加入Intuit之前, Smith 先生担任ADP的营销和业务发展高级副总裁,在这里从1996年到2003年他担任了好几个高管职务。 Smith 先生曾在雅虎的董事会工作。从2010年到2013年。 Smith 先生被任命为Nordstrom公司的董事。2013年6月,他是审计委员会和财务委员会的一个成员。 Smith 先生持有马歇尔大学的工商管理学士学位和阿奎那大学的硕士学位。
Brad D. Smith,was initially elected to the Board in September 2022. Mr. Smith is the President of Marshall University, having held this position since January 2022. Prior to joining Marshall, Mr. Smith was Executive Chairman of the Board of Intuit Inc. from January 2019 until January 2022 and Chairman from January 2016 until January 2019, following 11 years as Intuit's President and CEO from January 2008 until December 2018. Mr. Smith began his career at Intuit in February 2003, and prior to his time as President and CEO, he served in various leadership positions within the company. Prior to joining Intuit, Mr. Smith held several executive positions with ADP, where he served from 1996 to 2003. Mr. Smith holds a Bachelor of Business Administration degree from Marshall University and a Master's degree in Management from Aquinas College. Mr. Smith currently serves on the Board of Directors of Amazon.com, Inc.
Frank A. D'Amelio

Frank A. D'Amelio,自2010年12月起,他担任业务运营执行副总裁及财务总监。2007年9月至2010年12月,是高级副总裁兼财务总监。在加入辉瑞公司前,自2006年11月至2007年8月,他是阿尔卡特朗讯的整合高级执行副总裁及首席行政官。他是Zoetis公司和Humana公司的董事,是Humana公司审计委员会的主席。他是新泽西州独立学院基金会和吉伦布鲁尔学校的董事。


Frank A. D'Amelio,is the former Executive Vice President and Chief Financial Officer of Pfizer Inc., a global pharmaceutical company (June 2020 to May 2022), and a member of Pfizer's Senior Executive Leadership Team. Mr. D'Amelio currently serves as a CFO in residence at the Deloitte CFO Academy. From June 2020 through December 2021, Mr. D'Amelio also served as Pfizer's Executive Vice President, Global Supply and Business Operations. Mr. D'Amelio previously served as Pfizer's Executive Vice President, Business Operations and Global Supply and Chief Financial Officer from October 2018 until June 2020 and Executive Vice President, Business Operations and Chief Financial Officer from December 2010 to September 2018. He joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. During Mr. D'Amelio's tenure at Pfizer, he led many acquisitions and partnerships valued at nearly $200 billion, including numerous transformative transactions, such as the acquisition of Wyeth as well as the divestitures of the animal health, consumer health and mature products businesses, and oversaw the company's information technology function and global supply chain. From November 2006 to August 2007, Mr. D'Amelio was the Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent, S.A., a global telecommunications equipment company. From January 2006 to November 2006, Mr. D'Amelio was the Chief Operating Officer of Lucent Technologies, with responsibility for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. From May 2001 until January 2006, he was appointed Executive Vice President, Administration, and Chief Financial Officer of Lucent.In addition to his service on the Zoetis Board of Directors, Mr. D'Amelio currently serves as a member of the Board of Directors of Humana Inc. (since September 2003), Hewlett Packard Enterprise (since January 2023), and Catalent Inc. (since August 2023). He also formerly served as a member of the National Advisory Board of JPMorgan Chase & Co. Mr. D'Amelio earned his bachelor's degree in Accounting from St. Peter's College and his MBA in Finance from St. John's University. Mr. D'Amelio's global senior management experience, finance and operational expertise, and knowledge of the pharmaceuticals industry, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Frank A. D'Amelio,自2010年12月起,他担任业务运营执行副总裁及财务总监。2007年9月至2010年12月,是高级副总裁兼财务总监。在加入辉瑞公司前,自2006年11月至2007年8月,他是阿尔卡特朗讯的整合高级执行副总裁及首席行政官。他是Zoetis公司和Humana公司的董事,是Humana公司审计委员会的主席。他是新泽西州独立学院基金会和吉伦布鲁尔学校的董事。
Frank A. D'Amelio,is the former Executive Vice President and Chief Financial Officer of Pfizer Inc., a global pharmaceutical company (June 2020 to May 2022), and a member of Pfizer's Senior Executive Leadership Team. Mr. D'Amelio currently serves as a CFO in residence at the Deloitte CFO Academy. From June 2020 through December 2021, Mr. D'Amelio also served as Pfizer's Executive Vice President, Global Supply and Business Operations. Mr. D'Amelio previously served as Pfizer's Executive Vice President, Business Operations and Global Supply and Chief Financial Officer from October 2018 until June 2020 and Executive Vice President, Business Operations and Chief Financial Officer from December 2010 to September 2018. He joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. During Mr. D'Amelio's tenure at Pfizer, he led many acquisitions and partnerships valued at nearly $200 billion, including numerous transformative transactions, such as the acquisition of Wyeth as well as the divestitures of the animal health, consumer health and mature products businesses, and oversaw the company's information technology function and global supply chain. From November 2006 to August 2007, Mr. D'Amelio was the Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent, S.A., a global telecommunications equipment company. From January 2006 to November 2006, Mr. D'Amelio was the Chief Operating Officer of Lucent Technologies, with responsibility for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. From May 2001 until January 2006, he was appointed Executive Vice President, Administration, and Chief Financial Officer of Lucent.In addition to his service on the Zoetis Board of Directors, Mr. D'Amelio currently serves as a member of the Board of Directors of Humana Inc. (since September 2003), Hewlett Packard Enterprise (since January 2023), and Catalent Inc. (since August 2023). He also formerly served as a member of the National Advisory Board of JPMorgan Chase & Co. Mr. D'Amelio earned his bachelor's degree in Accounting from St. Peter's College and his MBA in Finance from St. John's University. Mr. D'Amelio's global senior management experience, finance and operational expertise, and knowledge of the pharmaceuticals industry, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Kurt J. Hilzinger

Kurt J. Hilzinger,于2003年7月,他最初选入董事会,并当选为董事会主席在2014年1月1日起生效。自2010年8月直至其获委任为主席,他担任首席董事。他是法院广场资本合伙有限公司的合伙人,并在自2007年11月起就担任此职务。在此之前,自2004年3月至2007年11月,他是美源伯根公司的董事;2002年10月至2007年11月,是美源伯根公司总裁和首席营运官;2001年8月至2002年10月,担任美源伯根公司的执行副总裁兼首席营运官。


Kurt J. Hilzinger,was initially elected to the Board in July 2003, and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from August 2010 until his appointment as Chairman. Mr. Hilzinger is a Partner at Court Square Capital Partners, an independent private equity firm, having held this position since November 2007. At Court Square, Mr. Hilzinger focuses principally on investments in the healthcare industry. Prior to that, he was a Director of AmerisourceBergen Corporation from March 2004 to November 2007; having previously served as President and Chief Operating Officer of AmerisourceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from August 2001 to October 2002. Mr. Hilzinger also serves on the Board of Directors of Outlook Therapeutics, Inc. and several privately held companies.
Kurt J. Hilzinger,于2003年7月,他最初选入董事会,并当选为董事会主席在2014年1月1日起生效。自2010年8月直至其获委任为主席,他担任首席董事。他是法院广场资本合伙有限公司的合伙人,并在自2007年11月起就担任此职务。在此之前,自2004年3月至2007年11月,他是美源伯根公司的董事;2002年10月至2007年11月,是美源伯根公司总裁和首席营运官;2001年8月至2002年10月,担任美源伯根公司的执行副总裁兼首席营运官。
Kurt J. Hilzinger,was initially elected to the Board in July 2003, and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from August 2010 until his appointment as Chairman. Mr. Hilzinger is a Partner at Court Square Capital Partners, an independent private equity firm, having held this position since November 2007. At Court Square, Mr. Hilzinger focuses principally on investments in the healthcare industry. Prior to that, he was a Director of AmerisourceBergen Corporation from March 2004 to November 2007; having previously served as President and Chief Operating Officer of AmerisourceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from August 2001 to October 2002. Mr. Hilzinger also serves on the Board of Directors of Outlook Therapeutics, Inc. and several privately held companies.
David T. Feinberg

David T. Feinberg,2010年3月起担任本公司董事。他自2011年7月起,担任UCLA Health System的总裁;2007年7月起,担任UCLA Hospital System的首席执行官,及协理副校长。担任上述职务之前,他是Resnick Neuropsychiatric Hospital NPH at UCLA的医疗总监。他是委员会认证的,儿童和青少年精神病学、成人精神病学和成瘾精神病方面的专业人士。他是 David Geffen School of Medicine at UCLA的临床精神病学教授。他现为Douglas Emmett, Inc.的董事,这是纽交所上市的房地产投资信托基金。1984年,他以优异的成绩毕业于University of California, Berkeley的经济学专业;1989年,以优等生毕业于University of Health Sciences/The Chicago Medical School。2002年,他从获得了Pepperdine University工商管理硕士学位。他当选为董事,是由于他对于医疗行业的丰富知识,以及管理大型国际知名医院系统的经验。


David T. Feinberg,was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg focused on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that Humana Inc. ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's various healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and pushed the Humana Inc. e of new platforms and tools, including an IT system called a Unified Data Architecture that allowed the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater focus on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Business Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry. Dr. Feinberg also serves on the Board of Directors of Douglas Emmett Inc.
David T. Feinberg,2010年3月起担任本公司董事。他自2011年7月起,担任UCLA Health System的总裁;2007年7月起,担任UCLA Hospital System的首席执行官,及协理副校长。担任上述职务之前,他是Resnick Neuropsychiatric Hospital NPH at UCLA的医疗总监。他是委员会认证的,儿童和青少年精神病学、成人精神病学和成瘾精神病方面的专业人士。他是 David Geffen School of Medicine at UCLA的临床精神病学教授。他现为Douglas Emmett, Inc.的董事,这是纽交所上市的房地产投资信托基金。1984年,他以优异的成绩毕业于University of California, Berkeley的经济学专业;1989年,以优等生毕业于University of Health Sciences/The Chicago Medical School。2002年,他从获得了Pepperdine University工商管理硕士学位。他当选为董事,是由于他对于医疗行业的丰富知识,以及管理大型国际知名医院系统的经验。
David T. Feinberg,was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg focused on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that Humana Inc. ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's various healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and pushed the Humana Inc. e of new platforms and tools, including an IT system called a Unified Data Architecture that allowed the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater focus on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Business Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry. Dr. Feinberg also serves on the Board of Directors of Douglas Emmett Inc.
Jorge S. Mesquita

Jorge S. Mesquita,自2012年3月14日起一直担任集团总裁,负责宝洁公司的新业务创造与创新和宠物护理,这是一家消费类产品的全球营销商。从2012年1月1日至2012年3月13日,担任集团总裁,负责特别任务。在此之前,2007年至2011年,他曾担任全球织物护理集团总裁;2001年至2007年,担任全球家庭护理总裁;2006年至2007年,担任商业产品和宝洁专业总裁。自1984年,他连续受聘于宝洁公司,担任不同的市场营销和领导职位。他获得佛罗里达理工学院的化学工程科学学士学位。


Jorge S. Mesquita,was initially elected to the Board in February 2021. Mr. Mesquita was formerly Chief Executive Officer of BlueTriton Brands from July 2021 until March 2022. In this role Mr. Mesquita led the company's initiatives to expand market leadership, advance commitment to sustainability and environmental stewardship and to realize the potential of the company's portfolio of water brands.Prior to joining BlueTriton Brands, Mr. Mesquita was formerly the Executive Vice President, Worldwide Chairman, Consumer of Johnson & Johnson (J&J) from December 2014 until February 2019, where he was responsible for increasing the competitiveness of J&J's consumer business through a comprehensive transformational strategy. In this role, Mr. Mesquita served on J&J's Executive Committee and led the Consumer Group Operating Committee. Prior to that, Mr. Mesquita spent 29 years with The Procter & Gamble Company (P&G), where he held various roles leading P&G consumer product business units. During his tenure at P&G, Mr. Mesquita served as Group President – New Business Creation and Innovation from March 2012 until June 2013, Group President – Special Assignment from January 2012 until March 2012, Group President, Global Fabric Care from 2007 to 2011 and President, Global Home Care from 2001 to 2007, also serving as President of Commercial Products and President of P&G Professional from 2006 to 2007. Mr. Mesquita currently serves on the Board of Directors of Mondelez International, Inc.
Jorge S. Mesquita,自2012年3月14日起一直担任集团总裁,负责宝洁公司的新业务创造与创新和宠物护理,这是一家消费类产品的全球营销商。从2012年1月1日至2012年3月13日,担任集团总裁,负责特别任务。在此之前,2007年至2011年,他曾担任全球织物护理集团总裁;2001年至2007年,担任全球家庭护理总裁;2006年至2007年,担任商业产品和宝洁专业总裁。自1984年,他连续受聘于宝洁公司,担任不同的市场营销和领导职位。他获得佛罗里达理工学院的化学工程科学学士学位。
Jorge S. Mesquita,was initially elected to the Board in February 2021. Mr. Mesquita was formerly Chief Executive Officer of BlueTriton Brands from July 2021 until March 2022. In this role Mr. Mesquita led the company's initiatives to expand market leadership, advance commitment to sustainability and environmental stewardship and to realize the potential of the company's portfolio of water brands.Prior to joining BlueTriton Brands, Mr. Mesquita was formerly the Executive Vice President, Worldwide Chairman, Consumer of Johnson & Johnson (J&J) from December 2014 until February 2019, where he was responsible for increasing the competitiveness of J&J's consumer business through a comprehensive transformational strategy. In this role, Mr. Mesquita served on J&J's Executive Committee and led the Consumer Group Operating Committee. Prior to that, Mr. Mesquita spent 29 years with The Procter & Gamble Company (P&G), where he held various roles leading P&G consumer product business units. During his tenure at P&G, Mr. Mesquita served as Group President – New Business Creation and Innovation from March 2012 until June 2013, Group President – Special Assignment from January 2012 until March 2012, Group President, Global Fabric Care from 2007 to 2011 and President, Global Home Care from 2001 to 2007, also serving as President of Commercial Products and President of P&G Professional from 2006 to 2007. Mr. Mesquita currently serves on the Board of Directors of Mondelez International, Inc.

高管简历

中英对照 |  中文 |  英文
Bruce D. Broussard

Bruce D. Broussard被任命为本公司的总裁和首席执行官并被选举进董事会。在每一种情况下,2013年1月1日生效完成了长达一年担任首席执行官角色的过渡计划。2011年12月,Broussard先生加入Humana担任总裁。在加入Humana之前,Broussard先生是McKesson Specialty/US Oncology, Inc的首席执行官。2010年12月,US Oncology被McKesson收购。在US Oncology,他担任了很多高级执行职位,包括首席财务官,总裁,首席执行官和董事会主席。Broussard先生也是商业圆桌会议成员和美国健康保险计划(AHIP)的董事会成员,也任职于AHIP执行委员会。


Bruce D. Broussard,serves as Director and Chief Executive Officer (Principal Executive Officer), having held these positions since January 1, 2013. Mr. Broussard was elected President upon joining the Company in December 2011 and served in that capacity through December 2012. Prior to joining the Company, Mr. Broussard was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Mr. Broussard served in a number of senior executive roles, including Chief Financial Officer, Chief Executive Officer, and Chairman of the Board.
Bruce D. Broussard被任命为本公司的总裁和首席执行官并被选举进董事会。在每一种情况下,2013年1月1日生效完成了长达一年担任首席执行官角色的过渡计划。2011年12月,Broussard先生加入Humana担任总裁。在加入Humana之前,Broussard先生是McKesson Specialty/US Oncology, Inc的首席执行官。2010年12月,US Oncology被McKesson收购。在US Oncology,他担任了很多高级执行职位,包括首席财务官,总裁,首席执行官和董事会主席。Broussard先生也是商业圆桌会议成员和美国健康保险计划(AHIP)的董事会成员,也任职于AHIP执行委员会。
Bruce D. Broussard,serves as Director and Chief Executive Officer (Principal Executive Officer), having held these positions since January 1, 2013. Mr. Broussard was elected President upon joining the Company in December 2011 and served in that capacity through December 2012. Prior to joining the Company, Mr. Broussard was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Mr. Broussard served in a number of senior executive roles, including Chief Financial Officer, Chief Executive Officer, and Chairman of the Board.
Susan M. Diamond

Susan M. Diamond,她一直担任Humana Inc.(一家综合健康和保健公司)的首席财务官(2021年以来)。Diamond女士此前曾担任Humana家庭解决方案总裁(2019年至2021年),以及Humana医疗保险高级副总裁(2017年至2019年)。她于2006年加入Humana,职业生涯的大部分时间在Humana的医疗保险和家庭业务担任各种财务和运营领导职务。在Humana之前,她曾在早期阶段、风险支持的技术公司担任各种财务领导职务6年,并在路易斯维尔的风险投资公司担任首席财务官5年,与各个行业的早期阶段公司合作。她目前在Humana拥有所有权权益的几家私人实体的董事会任职。


Susan M. Diamond,serves as Chief Financial Officer, having been elected to this position in June 2021, from her prior role as Segment President, Home Business. Ms. Diamond joined the Company in June 2004 and has spent the majority of her career in various leadership roles in the Medicare and Home businesses, with a particular passion and emphasis on growth and consumer segmentation strategies for the Company's individual Medicare Advantage and Stand-Alone Part D offerings. Ms. Diamond also served for two and a half years as the Enterprise Vice President of Finance, where she was responsible for enterprise planning and forecasting, trend analytics and had responsibility for each of the Company's line of business CFOs and controllers.
Susan M. Diamond,她一直担任Humana Inc.(一家综合健康和保健公司)的首席财务官(2021年以来)。Diamond女士此前曾担任Humana家庭解决方案总裁(2019年至2021年),以及Humana医疗保险高级副总裁(2017年至2019年)。她于2006年加入Humana,职业生涯的大部分时间在Humana的医疗保险和家庭业务担任各种财务和运营领导职务。在Humana之前,她曾在早期阶段、风险支持的技术公司担任各种财务领导职务6年,并在路易斯维尔的风险投资公司担任首席财务官5年,与各个行业的早期阶段公司合作。她目前在Humana拥有所有权权益的几家私人实体的董事会任职。
Susan M. Diamond,serves as Chief Financial Officer, having been elected to this position in June 2021, from her prior role as Segment President, Home Business. Ms. Diamond joined the Company in June 2004 and has spent the majority of her career in various leadership roles in the Medicare and Home businesses, with a particular passion and emphasis on growth and consumer segmentation strategies for the Company's individual Medicare Advantage and Stand-Alone Part D offerings. Ms. Diamond also served for two and a half years as the Enterprise Vice President of Finance, where she was responsible for enterprise planning and forecasting, trend analytics and had responsibility for each of the Company's line of business CFOs and controllers.
Vishal Agrawal

Vishal Agrawal担任首席战略和企业发展官,于2018年12月加入公司。在加入公司之前,Agrawal博士是Carlyle Group LP的高级顾问,自2017年10月至2018年12月担任该职位。之前, Agrawal博士是Ciox Health的总裁兼首席发展官,Ciox Health是2015年12月至2018年10月在美国最大的健康信息交换和信息服务组织发布。在加入Ciox Health之前,Agrawal博士曾担任Harris Healthcare的总裁 2013年1月至2015年12月的解决方案。


Vishal Agrawal,serves as Chief Strategy and Corporate Development Officer, having joined the Company in December 2018. Prior to joining the Company, Dr. Agrawal was Senior Advisor for The Carlyle Group L.P., having held that position from October 2017 to December 2018. Previously, Dr. Agrawal was President and Chief Growth Officer of Ciox Health, the largest health information exchange and release of information services organization in the U.S. from December of 2015 to October 2018. Prior to joining Ciox Health, Dr. Agrawal served as President of Harris Healthcare Solutions from January 2013 to December 2015.
Vishal Agrawal担任首席战略和企业发展官,于2018年12月加入公司。在加入公司之前,Agrawal博士是Carlyle Group LP的高级顾问,自2017年10月至2018年12月担任该职位。之前, Agrawal博士是Ciox Health的总裁兼首席发展官,Ciox Health是2015年12月至2018年10月在美国最大的健康信息交换和信息服务组织发布。在加入Ciox Health之前,Agrawal博士曾担任Harris Healthcare的总裁 2013年1月至2015年12月的解决方案。
Vishal Agrawal,serves as Chief Strategy and Corporate Development Officer, having joined the Company in December 2018. Prior to joining the Company, Dr. Agrawal was Senior Advisor for The Carlyle Group L.P., having held that position from October 2017 to December 2018. Previously, Dr. Agrawal was President and Chief Growth Officer of Ciox Health, the largest health information exchange and release of information services organization in the U.S. from December of 2015 to October 2018. Prior to joining Ciox Health, Dr. Agrawal served as President of Harris Healthcare Solutions from January 2013 to December 2015.
Sam M. Deshpande

Sam M. Deshpande目前担任首席风险官,自2017年7月加入公司以来一直担任此职位。在加入Humana之前,Deshpande先生在Capital One担任重要领导职务长达17年,最近担任该公司的首席风险官。 美国和国际卡业务。 他曾担任金融服务部业务首席风险官兼企业服务主管,负责业务风险,数据科学,数据质量,流程卓越和项目管理。 他还领导了房屋贷款,汽车金融和信用卡业务的营销和分析,负责业务战略,信贷,产品和营销。


Sam M. Deshpande,serves as Chief Information Officer, having been elected to this position in July 2021, from his prior role as Chief Technology and Risk Officer. Before joining the Company in July 2017, Mr. Deshpande spent 17 years at Capital One in key leadership positions, most recently as Business Chief Risk Officer for the U.S. and international card business. He previously served as the Business Chief Risk Officer and Head of Enterprise Services for the Financial Services Division, responsible for Business Risk, Data Science, Data Quality, Process Excellence and Project Management. He also led marketing and analysis for the Home Loans, Auto Finance, and Credit Card businesses, with responsibilities for business strategy, credit, product and marketing.
Sam M. Deshpande目前担任首席风险官,自2017年7月加入公司以来一直担任此职位。在加入Humana之前,Deshpande先生在Capital One担任重要领导职务长达17年,最近担任该公司的首席风险官。 美国和国际卡业务。 他曾担任金融服务部业务首席风险官兼企业服务主管,负责业务风险,数据科学,数据质量,流程卓越和项目管理。 他还领导了房屋贷款,汽车金融和信用卡业务的营销和分析,负责业务战略,信贷,产品和营销。
Sam M. Deshpande,serves as Chief Information Officer, having been elected to this position in July 2021, from his prior role as Chief Technology and Risk Officer. Before joining the Company in July 2017, Mr. Deshpande spent 17 years at Capital One in key leadership positions, most recently as Business Chief Risk Officer for the U.S. and international card business. He previously served as the Business Chief Risk Officer and Head of Enterprise Services for the Financial Services Division, responsible for Business Risk, Data Science, Data Quality, Process Excellence and Project Management. He also led marketing and analysis for the Home Loans, Auto Finance, and Credit Card businesses, with responsibilities for business strategy, credit, product and marketing.
William K. Fleming

William K. Fleming目前担任医疗保健服务部门总裁,负责Humana的所有Humana部门的临床和药房业务,自2017年3月起担任此职位。在此之前,他曾担任公司药房业务总裁。Fleming先生于1994年加入公司。


William K. Fleming,serves as Chief Corporate Affairs Officer, having been elected to this position in April 2023, from his prior role as Segment President, Pharmacy Solutions and Chief Corporate Affairs Officer. Prior to that, Dr. Fleming held positions of Segment President, Clinical and Pharmacy Solutions, Segment President, Healthcare Services, and President of the Company's pharmacy business. Dr. Fleming joined the Company in 1994.
William K. Fleming目前担任医疗保健服务部门总裁,负责Humana的所有Humana部门的临床和药房业务,自2017年3月起担任此职位。在此之前,他曾担任公司药房业务总裁。Fleming先生于1994年加入公司。
William K. Fleming,serves as Chief Corporate Affairs Officer, having been elected to this position in April 2023, from his prior role as Segment President, Pharmacy Solutions and Chief Corporate Affairs Officer. Prior to that, Dr. Fleming held positions of Segment President, Clinical and Pharmacy Solutions, Segment President, Healthcare Services, and President of the Company's pharmacy business. Dr. Fleming joined the Company in 1994.
Joseph C. Ventura

Joseph C. Ventura目前担任首席法律官和公司秘书。 彼于二零零九年一月加入本公司,并于二零零九年七月至二零一九年二月期间担任本公司法律部门的多个职位,包括最近担任高级副总裁,副总法律顾问及公司秘书。


Joseph C. Ventura,serves as Chief Legal Officer. He joined the Company in January 2009 and since then has held various positions of increasing responsibility in the Company's Law Department, including most recently, Senior Vice President, Associate General Counsel & Corporate Secretary from July 2017 until February 2019.
Joseph C. Ventura目前担任首席法律官和公司秘书。 彼于二零零九年一月加入本公司,并于二零零九年七月至二零一九年二月期间担任本公司法律部门的多个职位,包括最近担任高级副总裁,副总法律顾问及公司秘书。
Joseph C. Ventura,serves as Chief Legal Officer. He joined the Company in January 2009 and since then has held various positions of increasing responsibility in the Company's Law Department, including most recently, Senior Vice President, Associate General Counsel & Corporate Secretary from July 2017 until February 2019.
George Renaudin II

George Renaudin II目前担任医疗保险和医疗补助总裁,于2023年2月当选担任这一职务。他于2004年4月加入公司,此后担任各种领导职务,责任日益增加,最近担任医疗保险总裁。


George Renaudin II,services as President, Medicare & Medicaid, having been elected to this position in February 2023. Mr. Renaudin joined the Company in April 2004 and since then has held various leadership roles of increasing responsibility, most recently holding the position of President, Medicare.
George Renaudin II目前担任医疗保险和医疗补助总裁,于2023年2月当选担任这一职务。他于2004年4月加入公司,此后担任各种领导职务,责任日益增加,最近担任医疗保险总裁。
George Renaudin II,services as President, Medicare & Medicaid, having been elected to this position in February 2023. Mr. Renaudin joined the Company in April 2004 and since then has held various leadership roles of increasing responsibility, most recently holding the position of President, Medicare.
John Paul W. Felter

John Paul W. Felter目前担任高级副总裁、首席会计官和财务总监,已于2022年8月当选。加入Humana Inc.公司之前,Felter先生于2022年5月至2022年6月担任OneAmerica Financial Partners,Inc.的投资融资高级总监。在加入OneAmerica之前,Felter先生在安永会计师事务所(Ernst&Young LLP)担任了近11年的高级经理,负责监督公共和私人实体的大型审计业务,专注于医疗保险行业。


John Paul W. Felter,serves as Senior Vice President, Chief Accounting Officer and Controller, having been elected to this position in August 2022. Before joining the Company, Mr. Felter served as Senior Director - Investment Finance for OneAmerica Financial Partners, Inc. in 2022. Prior to OneAmerica, Mr. Felter spent nearly 11 years in multiple roles of increasing responsibility at Ernst & Young LLP where he oversaw large audit engagements for public and private entities with a concentration in the health insurance sector.
John Paul W. Felter目前担任高级副总裁、首席会计官和财务总监,已于2022年8月当选。加入Humana Inc.公司之前,Felter先生于2022年5月至2022年6月担任OneAmerica Financial Partners,Inc.的投资融资高级总监。在加入OneAmerica之前,Felter先生在安永会计师事务所(Ernst&Young LLP)担任了近11年的高级经理,负责监督公共和私人实体的大型审计业务,专注于医疗保险行业。
John Paul W. Felter,serves as Senior Vice President, Chief Accounting Officer and Controller, having been elected to this position in August 2022. Before joining the Company, Mr. Felter served as Senior Director - Investment Finance for OneAmerica Financial Partners, Inc. in 2022. Prior to OneAmerica, Mr. Felter spent nearly 11 years in multiple roles of increasing responsibility at Ernst & Young LLP where he oversaw large audit engagements for public and private entities with a concentration in the health insurance sector.
James A. Rechtin

James A. Rechtin, 2011年加入Humana, 2013年担任首席执行官。在过去的十年中,他领导公司从一家健康保险公司转型为今天的更广泛的医疗保健公司,将健康保险与医疗保健服务相结合。Rechtin从Envision Healthcare加入Humana,担任总裁兼首席执行官。他拥有超过22年的医疗保健经验,专注于在各种医疗集团环境中提供基于价值的护理,包括对医疗保险优势的深刻理解。加入Envision之前,Rechtin担任OptumCare (UnitedHealth Group的一部分)的总裁。在加入OptumCare之前,Rechtin于2014年加入DaVita Medical Group,担任战略高级副总裁和DaVita Medical Group加利福尼亚市场总裁。此外,他是Bain & Company的14年资深员工,突出了他在医疗保健合并和整体医疗保健行业的丰富经验。雷克廷是肯塔基人,他的职业生涯始于印第安纳波利斯一家非营利性健康和人类服务诊所的运营,并在刚果的美国和平队服役。他获得了哈佛商学院工商管理硕士学位和德堡大学文学学士学位。他担任DePauw board of Visitors的董事会成员。


James A. Rechtin,serves as President and Chief Operating Officer, having been elected to this position in January 2024. Prior to joining the Company, Mr. Rechtin served as President and CEO at Envision Healthcare, having held that position from 2020 to 2023. Previously, Mr. Rechtin was President of OptumCare in 2019 after serving in multiple senior-level roles at Davita Medical Group from 2014 to 2019.
James A. Rechtin, 2011年加入Humana, 2013年担任首席执行官。在过去的十年中,他领导公司从一家健康保险公司转型为今天的更广泛的医疗保健公司,将健康保险与医疗保健服务相结合。Rechtin从Envision Healthcare加入Humana,担任总裁兼首席执行官。他拥有超过22年的医疗保健经验,专注于在各种医疗集团环境中提供基于价值的护理,包括对医疗保险优势的深刻理解。加入Envision之前,Rechtin担任OptumCare (UnitedHealth Group的一部分)的总裁。在加入OptumCare之前,Rechtin于2014年加入DaVita Medical Group,担任战略高级副总裁和DaVita Medical Group加利福尼亚市场总裁。此外,他是Bain & Company的14年资深员工,突出了他在医疗保健合并和整体医疗保健行业的丰富经验。雷克廷是肯塔基人,他的职业生涯始于印第安纳波利斯一家非营利性健康和人类服务诊所的运营,并在刚果的美国和平队服役。他获得了哈佛商学院工商管理硕士学位和德堡大学文学学士学位。他担任DePauw board of Visitors的董事会成员。
James A. Rechtin,serves as President and Chief Operating Officer, having been elected to this position in January 2024. Prior to joining the Company, Mr. Rechtin served as President and CEO at Envision Healthcare, having held that position from 2020 to 2023. Previously, Mr. Rechtin was President of OptumCare in 2019 after serving in multiple senior-level roles at Davita Medical Group from 2014 to 2019.
Sanjay K. Shetty

Sanjay K. Shetty,目前担任CenterWell总裁,已于2023年4月当选这一职位。在加入公司之前,Shetty博士在Steward Health Care System工作了近13年,担任过多个高级职务,包括Steward North America总裁、Steward South Region总裁和执行副总裁、Steward Medical Group总裁和Steward Health Care System执行副总裁、企业和业务发展执行副总裁以及Steward Health Care Network总裁。


Sanjay K. Shetty,serves as President, CenterWell, having been elected to this position in April 2023. Prior to joining the Company, Dr. Shetty spent nearly 13 years at Steward Health Care System in multiple senior-level roles, including President of Steward North America, President, Steward South Region and Executive Vice President, President, Steward Medical Group and Executive Vice President, Steward Health Care System, Executive Vice President for Corporate and Business Development, and President, Steward Health Care Network.
Sanjay K. Shetty,目前担任CenterWell总裁,已于2023年4月当选这一职位。在加入公司之前,Shetty博士在Steward Health Care System工作了近13年,担任过多个高级职务,包括Steward North America总裁、Steward South Region总裁和执行副总裁、Steward Medical Group总裁和Steward Health Care System执行副总裁、企业和业务发展执行副总裁以及Steward Health Care Network总裁。
Sanjay K. Shetty,serves as President, CenterWell, having been elected to this position in April 2023. Prior to joining the Company, Dr. Shetty spent nearly 13 years at Steward Health Care System in multiple senior-level roles, including President of Steward North America, President, Steward South Region and Executive Vice President, President, Steward Medical Group and Executive Vice President, Steward Health Care System, Executive Vice President for Corporate and Business Development, and President, Steward Health Care Network.
Timothy S. Huval

Timothy S. Huval,他目前担任高级副总裁兼首席人力资源官,在2012年12月已当选了这个位置。在加入公司前,他在美国银行工作了10年,并担任多个高层职位,包括全球财富与投资管理的人力资源高管和首席信息官,以及全球资金服务和技术与全球运营的人力资源高管。


Timothy S. Huval,serves as Chief Administrative Officer, having been elected to this position in July 2019, from his previous role as Chief Human Resources Officer. Prior to joining the Company, Mr. Huval spent 10 years at Bank of America in multiple senior-level roles, including Human Resources executive and Chief Information Officer for Global Wealth & Investment Management, as well as Human Resources executive for both Global Treasury Services and Technology & Global Operations.
Timothy S. Huval,他目前担任高级副总裁兼首席人力资源官,在2012年12月已当选了这个位置。在加入公司前,他在美国银行工作了10年,并担任多个高层职位,包括全球财富与投资管理的人力资源高管和首席信息官,以及全球资金服务和技术与全球运营的人力资源高管。
Timothy S. Huval,serves as Chief Administrative Officer, having been elected to this position in July 2019, from his previous role as Chief Human Resources Officer. Prior to joining the Company, Mr. Huval spent 10 years at Bank of America in multiple senior-level roles, including Human Resources executive and Chief Information Officer for Global Wealth & Investment Management, as well as Human Resources executive for both Global Treasury Services and Technology & Global Operations.